Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Romidepsin

FDA-approved product (powder, intravenous), marketed as Istodax, Romidepsin.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Romidepsin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous T-cell lymphoma
  • Mature T-cell and NK-cell non-Hodgkin lymphoma
  • Neoplasm
  • T-cell non-Hodgkin lymphoma
  • Unspecified peripheral T-cell lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Histone deacetylase (hdac) inhibitors
FDA pharmacologic class
Histone Deacetylase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Romidepsin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-3.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-2.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-3.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Romidepsin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

    NCT02512172 · start 2016-02-19

    Registered record
    Registry ID
    NCT02512172
    Conditions
    Colorectal Cancer
    Interventions
    Oral CC-486; Romidepsin; MK-3475
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-19
    Completion
    2021-11-20
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionOral CC-486; Romidepsin; MK-3475
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

    NCT02616874 · start 2016-02

    Registered record
    Registry ID
    NCT02616874
    Conditions
    HIV
    Interventions
    MVA.HIVconsv vaccine; Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02
    Completion
    2017-10-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionMVA.HIVconsv vaccine; Romidepsin
    PhasePhase 1
    Registry statusCompleted

  • Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

    NCT02181218 · start 2015-02-04

    Registered record
    Registry ID
    NCT02181218
    Conditions
    Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse
    Interventions
    Romidepsin; Gemcitabine; Oxaliplatin; Dexamethasone; Pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-02-04
    Completion
    2020-06-26
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse
    InterventionRomidepsin; Gemcitabine; Oxaliplatin; Dexamethasone +1 more
    PhasePhase 1
    Registry statusCompleted

  • Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

    NCT02341014 · start 2015-01-02

    Registered record
    Registry ID
    NCT02341014
    Conditions
    T-cell Lymphomas; Relapsed or Refractory
    Interventions
    Carfilzomib; Romidepsin; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-01-02
    Completion
    2023-01-11
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT-cell Lymphomas; Relapsed or Refractory
    InterventionCarfilzomib; Romidepsin; Lenalidomide
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease

    NCT02203578 · start 2014-11

    Registered record
    Registry ID
    NCT02203578
    Conditions
    Graft Versus Host Disease
    Interventions
    romidepsin; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2014-11
    Completion
    2016-06-14
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft Versus Host Disease
    Interventionromidepsin; laboratory biomarker analysis
    PhaseNot applicable
    Registry statusTerminated

  • Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

    NCT02223208 · start 2014-09

    Registered record
    Registry ID
    NCT02223208
    Conditions
    Peripheral T-cell Lymphomas (PTCL); PTCL-NOS; Angioimmunoblastic T-cell Lymphoma (AITL); ALK- Anaplastic Large Cell Lymphoma (ALCL); Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin
    Interventions
    Ro-CHOEP-21 (PHASE I); Ro-CHOEP-21 (PHASE II)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-09
    Completion
    2026-03-25
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T-cell Lymphomas (PTCL); PTCL-NOS; Angioimmunoblastic T-cell Lymphoma (AITL); ALK- Anaplastic Large Cell Lymphoma (ALCL) +1 more
    InterventionRo-CHOEP-21 (PHASE I); Ro-CHOEP-21 (PHASE II)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

    NCT01933594 · start 2014-05-05

    Registered record
    Registry ID
    NCT01933594
    Conditions
    HIV Infections
    Interventions
    Romidepsin; Placebo for Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-05-05
    Completion
    2018-04-16
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRomidepsin; Placebo for Romidepsin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

    NCT01902225 · start 2014-03-04

    Registered record
    Registry ID
    NCT01902225
    Conditions
    Lymphoma; T-Cell Lymphoma; Cutaneous Lymphoma
    Interventions
    Istodax; Doxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03-04
    Completion
    2020-04-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; T-Cell Lymphoma; Cutaneous Lymphoma
    InterventionIstodax; Doxil
    PhasePhase 1
    Registry statusCompleted

  • Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

    NCT02061449 · start 2014-03

    Registered record
    Registry ID
    NCT02061449
    Conditions
    Cutaneous T-cell Lymphoma
    Interventions
    Romidepsin; Poly ICLC; Focal lesional radiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2014-03
    Completion
    2018-11-05
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous T-cell Lymphoma
    InterventionRomidepsin; Poly ICLC; Focal lesional radiation
    PhasePhase 1
    Registry statusTerminated

  • Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

    NCT02092116 · start 2014-03

    Registered record
    Registry ID
    NCT02092116
    Conditions
    HIV I Infection
    Interventions
    Romidepsin; Vacc-4x; rhuGM-CSF
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    2015-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV I Infection
    InterventionRomidepsin; Vacc-4x; rhuGM-CSF
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

    NCT01947140 · start 2013-09-09

    Registered record
    Registry ID
    NCT01947140
    Conditions
    Lymphoid Malignancies; Multiple Myeloma; Lymphoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma
    Interventions
    Pralatrexate; Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2013-09-09
    Completion
    2022-09-01
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoid Malignancies; Multiple Myeloma; Lymphoma; Hodgkin Lymphoma +1 more
    InterventionPralatrexate; Romidepsin
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma

    NCT01913119 · start 2013-07

    Registered record
    Registry ID
    NCT01913119
    Conditions
    Histologically Proven Extranodal NKTcell Lymphoma
    Interventions
    Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2013-07
    Completion
    2013-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHistologically Proven Extranodal NKTcell Lymphoma
    InterventionRomidepsin
    PhaseEarly phase 1
    Registry statusCompleted

  • Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

    NCT01738594 · start 2013-03-22

    Registered record
    Registry ID
    NCT01738594
    Conditions
    Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IA Mycosis Fungoides/Sezary Syndrome; Stage IB Mycosis Fungoides/Sezary Syndrome; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IIA Mycosis Fungoides/Sezary Syndrome; Stage IIB Mycosis Fungoides/Sezary Syndrome; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IIIA Mycosis Fungoides/Sezary Syndrome; Stage IIIB Mycosis Fungoides/Sezary Syndrome; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IVA Mycosis Fungoides/Sezary Syndrome; Stage IVB Mycosis Fungoides/Sezary Syndrome
    Interventions
    carfilzomib; romidepsin; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2013-03-22
    Completion
    2016-10-11
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IA Mycosis Fungoides/Sezary Syndrome +10 more
    Interventioncarfilzomib; romidepsin; laboratory biomarker analysis
    PhasePhase 1
    Registry statusTerminated

  • Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

    NCT01796002 · start 2013-01

    Registered record
    Registry ID
    NCT01796002
    Conditions
    Peripheral T-cell Lymphoma
    Interventions
    Romidepsin + CHOP; CHOP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01
    Completion
    2022-12-13
    Enrolment
    421

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T-cell Lymphoma
    InterventionRomidepsin + CHOP; CHOP
    PhasePhase 3
    Registry statusCompleted

  • Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

    NCT01822886 · start 2013-01

    Registered record
    Registry ID
    NCT01822886
    Conditions
    Peripheral T-cell Lymphoma
    Interventions
    Romidepsin + Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-01
    Completion
    2018-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T-cell Lymphoma
    InterventionRomidepsin + Gemcitabine
    PhasePhase 2
    Registry statusCompleted